Glycolipopeptide Antibodies for Self-Assembling Vaccine Immunogens
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer vaccines based on carbohydrate antigens face challenges due to the limited immunogenicity of carbohydrates, which fail to activate helper T-cells effectively, leading to inadequate immune responses, especially when conjugated to foreign carrier proteins, and result in ambiguities in composition and structure, and potential suppression of antibody responses.
Innovation Solution
Development of a fully synthetic glycolipopeptide that combines a B-epitope and a T-epitope with a lipid component, facilitating self-assembly into vesicles and acting as a built-in adjuvant to enhance immune response, specifically incorporating a Toll-like receptor ligand to improve antigen presentation and cytokine production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If carbohydrates are conjugated to foreign carrier proteins to enhance immunogenicity, then helper T-cell activation is improved, but composition ambiguity and structure ambiguities occur
Solution Approach 1:
The invention divides the immunogen into separate modular components: a carbohydrate component (containing B-epitope), a peptide component (containing T-epitope), and an optional linker. This segmentation allows each component to be independently synthesized with defined structures, eliminating the composition ambiguity that arises from conventional carbohydrate-protein conjugation while maintaining both B-cell and T-cell immunogenicity.
2Reliability
If carbohydrates are conjugated to carrier proteins to activate helper T-cells, then T-cell activation is improved, but antibody response suppression occurs
Solution Approach 1:
The invention extracts the carrier protein function from the immunogen structure by using a separate, well-defined peptide component that provides T-epitopes. This peptide can be synthesized with precise amino acid sequences that are known to activate helper T-cells without causing epitope suppression, thereby maintaining T-cell activation while avoiding the harmful effects of foreign carrier proteins.
3Device complexity
If conventional carbohydrate vaccines are used, then simplicity of design is maintained, but immune response adequacy is insufficient
Solution Approach 1:
The invention merges the functions of B-cell epitope presentation and T-cell activation into a single integrated glycolipopeptide immunogen. The carbohydrate component presents B-epitopes while the peptide component provides T-epitopes, and they are linked through a defined structure. This combination achieves adequate immune response (both humoral and cellular) while maintaining relatively simple design compared to conventional conjugate vaccines.
Data Source
AI summary
A glycolipopeptide comprising a carbohydrate component, a peptide component and a lipid component, for use as a therapeutic or prophylactic vaccine. Also provided are monoclonal and polyclonal antibodies that recognize the glycolipopeptide of the invention, as well as uses thereof.